In this study, we evaluated the clinical effects of glucagon-like peptide-1 (GLP-1) receptor agonist (RA) therapy in a small, de-identified cohort of pediatric patients with MASLD and investigated potential molecular mechanisms using publicly available transcriptomic datasets from models of liver disease. Here, GLP1R is linked to liver disorder.